Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (51)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Peterson, T.G.
Right arrow Articles by Barnes, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peterson, T.G.
Right arrow Articles by Barnes, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 Oxford University Press

research-article

The role of metabolism in mammary epithelial cell growth inhibition by the isoflavones genistein and biochanin A

T.Greg Peterson 2, Lori Coward 1, Marion Kirk 3, Charles N. Falany 1 and Stephen Barnes 1 2 3 4

1Departments of Pharmacology and Toxicology, University of Alabama at Birmingham Birmingham, AL 35294, USA
2Departments of Biochemistry and Molecular Genetics, University of Alabama at Birmingham Birmingham, AL 35294, USA
3Departments of Comprehensive Cancer Center Mass Spectrometry Shared Facility, University of Alabama at Birmingham Birmingham, AL 35294, USA

4To whom correspondence should be addressed at: the Department of Pharmacology and Toxicology

The basis for the differential sensitivity of cultured normal human mammary epithelial (HME) cells and a transformed human breast cancer MCF-7 cell line to growth inhibition by the isoflavone genistein and its 4'-methyl ether derivative, biochanin A, was examined. In HME cells genistein is 5-fold more potent as a growth inhibitor than biochanin A, whereas in MCF-7 cells biochanin A and genistein are equally potent as growth inhibitors. Based on its properties as an in vitro protein tyrosine kinase (PTK) inhibitor, biochanin A would be expected to be a less potent growth inhibitor than genistein. To determine whether isoflavone metabolism could account for the observed differences in growth inhibition, metabolism experiments were conducted with HME and MCF-7 cells using [4-14C]genistein and [4-14C]biochanin A. MCF-7 cells extensively metabolized both isoflavones, producing two genistein metabolites with molecular weights of 350 and 380 and three biochanin A metabolites with molecular weights of 270, 350 and 380. In contrast, significant genistein or biochanin A metabolism was not observed in HME cells. Using mass spectrometry and nuclear magnetic resonance analysis, metabolite 350 from genistein and biochanin A experiments was identified as genistein 7-sulfate; biochanin A metabolite 270 was identified as genistein. Metabolite 380 was not unequivocally identified, but appeared to be a hydroxylated and methylated form of genistein sulfate. In MCF-7 cells, genistein 7-sulfate and metabolite 380 were detected primarily in the cell media fraction, suggesting that once formed these polar metabolites were excreted from the cells. These data show that isoflavone metabolism by transformed breast epithelial cells modulates the growth inhibitory effects of genistein and biochanin A. In MCF-7 cells, genistein metabolism was correlated with a decrease in growth inhibition, whereas biochanin A metabolism was associated with an increase in growth inhibition.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
L. A. Korde, A. H. Wu, T. Fears, A. M.Y. Nomura, D. W. West, L. N. Kolonel, M. C. Pike, R. N. Hoover, and R. G. Ziegler
Childhood Soy Intake and Breast Cancer Risk in Asian American Women
Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1050 - 1059.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
T. K. Choueiri, T. Mekhail, T. E. Hutson, R. Ganapathi, G. E. Kelly, and R. M. Bukowski
Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer
Ann. Onc., May 1, 2006; 17(5): 860 - 865.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
T. E. Hedlund, P. D. Maroni, P. G. Ferucci, R. Dayton, S. Barnes, K. Jones, R. Moore, L. G. Ogden, K. Wahala, H. M. Sackett, et al.
Long-Term Dietary Habits Affect Soy Isoflavone Metabolism and Accumulation in Prostatic Fluid in Caucasian Men
J. Nutr., June 1, 2005; 135(6): 1400 - 1406.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
M. J. Messina and C. L. Loprinzi
Soy for Breast Cancer Survivors: A Critical Review of the Literature
J. Nutr., November 1, 2001; 131(11): 3095S - 3108.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. R. Doerge, H. C. Chang, M. I. Churchwell, and C. L. Holder
Analysis of Soy Isoflavone Conjugation In Vitro and in Human Blood Using Liquid Chromatography-Mass Spectrometry
Drug Metab. Dispos., March 1, 2000; 28(3): 298 - 307.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
S. Barnes, H. Kim, V. Darley-Usmar, R. Patel, J. Xu, B. Boersma, and M. Luo
Beyond ER{alpha} and ER{beta}: Estrogen Receptor Binding Is Only Part of the Isoflavone Story
J. Nutr., March 1, 2000; 130(3): 656 - 656.
[Full Text]


Home page
Am. J. Clin. Nutr.Home page
M. J Messina
Legumes and soybeans: overview of their nutritional profiles and health effects
Am. J. Clinical Nutrition, September 1, 1999; 70(3): 439S - 450.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
G. G. J. M. Kuiper, J. G. Lemmen, B. Carlsson, J. C. Corton, S. H. Safe, P. T. van der Saag, B. van der Burg, and J.-A. Gustafsson
Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor {beta}
Endocrinology, October 1, 1998; 139(10): 4252 - 4263.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.